Hydantoins: Structure, Pharmacology, and Clinical Use of Phenytoin and Derivatives
Hydantoins (imidazolidine-2,4-diones) are heterocyclic compounds with a five-membered ring containing two nitrogens and two carbonyl groups. Phenytoin, the prototype anticonvulsant, has defined this drug class for decades.
Chemical Structure
- Core: Imidazolidine-2,4-dione (cyclic ureide)
- 5-position substitution (phenyl in phenytoin) confers anticonvulsant activity
- pKa ~8.3; weak acid; poorly water-soluble (parenteral forms require propylene glycol/ethanol at pH 12)
Pharmacology
Mechanism of Action (Phenytoin)
- Use-dependent blockade of voltage-gated sodium channels → stabilizes neuronal membranes, limits high-frequency repetitive firing
- No effect on normal synaptic transmission at therapeutic doses
Pharmacokinetics
- Oral absorption: slow, erratic (pH-dependent, saturable)
- Protein binding: ~90% to albumin; free fraction is pharmacologically active
- Metabolism: Hepatic CYP2C9/2C19 → p-HPPH glucuronide
- Zero-order kinetics at therapeutic doses (enzyme saturation) → small dose changes produce large plasma level changes
- Half-life: 12–36 hours (dose-dependent)
- Induces CYP3A4, CYP2C → numerous drug interactions
Clinical Uses
- Phenytoin: Focal and generalized tonic-clonic seizures; status epilepticus; neurosurgery prophylaxis. Not for absence or myoclonic seizures.
- Fosphenytoin (prodrug): IV/IM administration; safer, faster, no propylene glycol
- Mephenytoin (historical): CYP2C19 probe substrate
- Dantrolene (hydantoin derivative): Malignant hyperthermia, spasticity (ryanodine receptor antagonist)
Adverse Effects
- Acute: Nystagmus, ataxia, dysarthria (dose-related); IV hypotension/arrhythmia (propylene glycol vehicle)
- Chronic: Gingival hyperplasia (30–50%), hirsutism, coarsening facial features, osteomalacia (vitamin D catabolism), folate deficiency, peripheral neuropathy
- Idiosyncratic: SJS/TEN, DRESS syndrome, hepatitis, lupus-like syndrome, cytopenias
Therapeutic Drug Monitoring
- Total: 10–20 µg/mL; Free: 1–2 µg/mL (preferred in hypoalbuminemia, renal failure, pregnancy)
- Trough levels; adjust for protein binding: Corrected = Measured / [(0.1 × albumin) + 0.1]
Lyme Disease - Related Articles
- Lymphangitis Treatment: Antibiotics, Drainage, and Supportive Care
- Delta Variant: Understanding Its Risks and How to Protect Yourself
- Understanding and Managing Lyme Disease Symptoms: A Comprehensive Guide
- Understanding Lyme Disease: Symptoms, Transmission & Prevention
- Lyme Disease: Symptoms, Long-Term Effects & Treatment Options
- Delta Variant Protection: Vaccines, Boosters, and Preventive Measures
- Hymenoplasty: Timing, Procedure, Risks & Considerations
